Valuation: Lexaria Corp

Market Cap 51.72L 45.55L 43.15L 38.96L 73.43L 50Cr 74.38L 5.16Cr 1.99Cr 25Cr 1.94Cr 1.9Cr 81Cr P/E 2026 *
-0.77x
P/E 2027 * -0.67x
Enterprise Value 51.72L 45.55L 43.15L 38.96L 73.43L 50Cr 74.38L 5.16Cr 1.99Cr 25Cr 1.94Cr 1.9Cr 81Cr EV / Sales 2026 *
259x
EV / Sales 2027 * 3.69x
Free-Float
96.68%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2024
Director of Finance/CFO 66 01/10/2024
President 55 15/04/2015
Director TitleAgeSince
Chairman 65 26/10/2006
Director/Board Member 72 08/07/2011
Director/Board Member 55 29/04/2016
Change 5-day change 1-year change 3-year change Capi.($)
-2.35%+1.14%+52.57%+116.26% 1,05600Cr
-1.01%-1.49%+43.00%+70.90% 64TCr
-0.50%-0.82%+13.55%+77.34% 47TCr
-2.61%-1.30%+74.13%+42.52% 37TCr
-0.06%-3.88%+34.32%+40.74% 34TCr
-0.79%+2.01%+19.82%+28.48% 28TCr
-1.19%-1.21%+9.82%+12.15% 25TCr
-0.64%+4.06%+49.75%+58.68% 23TCr
-1.39%-1.10%+34.87%+102.04% 19TCr
Average -1.00%-0.25%+36.87%+61.01% 42.4TCr
Weighted average by Cap. -1.20%-0.22%+40.42%+72.67%

Financials

2026 *2027 *
Net sales 20T 17.61T 16.69T 15.06T 28.39T 19.18L 28.76T 2L 76.83T 10L 75.1T 73.46T 31.43L 14.03L 12.35L 11.71L 10.57L 19.92L 13Cr 20.18L 1.4Cr 53.9L 6.88Cr 52.68L 51.53L 22Cr
Net income -66.39L -58.46L -55.39L -50.01L -94.25L -64Cr -95.47L -6.63Cr -2.55Cr -33Cr -2.49Cr -2.44Cr -104.33Cr -89.47L -78.79L -74.65L -67.39L -1.27Cr -86Cr -1.29Cr -8.93Cr -3.44Cr -44Cr -3.36Cr -3.29Cr -140.6Cr
Net Debt - -
Logo Lexaria Corp
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Employees
-